FindMyKOL
Clinical trialNCT02468492CompletedPhase Early 1Interventional

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

NCT02468492 is a phase early 1 interventional trial sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center. As of 21 Nov 2026, it is completed. It studies Platelet Rich Plasma in Knee Osteoarthritis. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 30 Sept 2014 and a primary completion date of 30 Nov 2015.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02468492
FieldValue
Registry IDNCT02468492
StatusCompleted
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorHunter Holmes Mcguire Veteran Affairs Medical Center
Enrollment18
Registered sites1
Countries1
ConditionsKnee Osteoarthritis
DrugsPlatelet Rich Plasma
Start30 Sept 2014
Primary completion30 Nov 2015
Study completion30 Nov 2015
Last update posted16 Aug 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the affect that platelet rich plasma has on the molecular an cellular functioning of the knee joint.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Virginia, United States1 site
  • Hunter Holmes Mcguire Va Medical Center

    Richmond

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginia: 1 siteVA1MarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Platelet Rich Plasma
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02468492

Each answer restates registry values shown on this page.

What is NCT02468492?

NCT02468492 is a phase early 1 interventional trial sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center. It studies Platelet Rich Plasma in Knee Osteoarthritis.

Who leads NCT02468492?

The registry names Lance L Goetz, MD (principal investigator, Hunter Holmes McGuire VAMC) as the overall official.

Where does NCT02468492 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02468492 study?

The registered drug and biological interventions are Platelet Rich Plasma.

When did NCT02468492 end?

The registry lists a primary completion date of 30 Nov 2015 and a study completion date of 30 Nov 2015. The sponsor last updated the record on 16 Aug 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.